Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial

NCT00125164 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00125164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00125164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2004
Completion date
July 31, 2008
Enrollment
137 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

growth disorders, insulin-like growth factor-1 deficiency